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Abstract
BCL6 is a transcriptional repressor that is over-expressed due to chromosomal translocations, or other abnormalities, in
,40% of diffuse large B-cell lymphoma. BCL6 interacts with co-repressor, SMRT, and this is essential for its role in
lymphomas. Peptide or small molecule inhibitors, which prevent the association of SMRT with BCL6, inhibit transcriptional
repression and cause apoptosis of lymphoma cells in vitro and in vivo. In order to discover compounds, which have the
potential to be developed into BCL6 inhibitors, we screened a natural product library. The ansamycin antibiotic, rifamycin
SV, inhibited BCL6 transcriptional repression and NMR spectroscopy confirmed a direct interaction between rifamycin SV
and BCL6. To further determine the characteristics of compounds binding to BCL6-POZ we analyzed four other members of
this family and showed that rifabutin, bound most strongly. An X-ray crystal structure of the rifabutin-BCL6 complex
revealed that rifabutin occupies a partly non-polar pocket making interactions with tyrosine58, asparagine21 and arginine24
of the BCL6-POZ domain. Importantly these residues are also important for the interaction of BLC6 with SMRT. This work
demonstrates a unique approach to developing a structure activity relationship for a compound that will form the basis of a
therapeutically useful BCL6 inhibitor.
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Introduction
BCL6 is a transcriptional repressor [1] that accomplishes its
effects by binding to DNA through carboxy-terminal zinc fingers
and recruitment of co-repressors to its mid-portion and amino-
terminus (Figure 1A). Co-repressors NCoR (NCOR1), BCoR
(BCOR) and SMRT (NCOR2), which are components of multi-
protein complexes that include histone deacetylases, associate
with the amino-terminal POZ domain [2–4]. SMRT and NCoR
share an amino acid sequence (GRSIHEIPR) that is required for
binding to the BCL6-POZ domain and is functionally important
[5] but in contrast BCoR binding is by means of a different
primary sequence (APSSWVVPG) [6]. The binding of co-
repressor, SMRT, to the BCL6-POZ domain has been shown to
be required for BCL6 function in B-cells, although it may be
dispensable for its function in T-cells [7]. SMRT is a scaffold
protein that mediates the recruitment of the HDAC3 repression
complex to BCL6 and other repressive transcription factors [8].
BCL6 is expressed in normal germinal center B-cells [9] and is
essential for high affinity antibody formation [10,11]. At a
cellular level its role may be to allow proliferation and inhibit
differentiation to plasma cells [12]. It has been demonstrated that
BCL6 promotes the proliferation of primary tonsillar B-cells [13]
and prevents terminal differentiation to plasma cells in B-cell
lines [12,14].
BCL6 is involved in chromosomal translocations in ,25% of all
cases of diffuse large B-cell lymphoma (DLBCL) [15] and is,
therefore, likely to have a major role in driving lymphomagenesis.
This is supported by the finding that mice with constitutive B-cell
expression of BCL6 develop lymphomas similar to human
DLBCL [16]. Gene expression profiling has been utilized to
subtype DLBCL into groups with differing clinical outcomes
[17,18]. The majority of cases with BCL6 translocations are
associated with poor prognosis activated B-cell (ABC) DLBCL
[19] as defined by the ‘‘cell of origin’’ classification [18,20]. Other
mechanisms causing constitutive expression of BCL6 have been
described; mutations disrupting a negative regulatory site in the
promoter region of the BCL6 gene occur in 10 to 15% of DLBCL
[21,22] and disruption of normal post-translational regulation of
BCL6 by various mechanisms have also been reported and are
likely to contribute to deregulated expression [23–25]. Overall
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BCL6 is an important oncogene in DLBCL but it is also expressed
from an un-rearranged locus in follicular lymphoma, Burkitt’s
lymphoma and nodular lymphocyte predominant Hodgkin’s
lymphoma. Although its role has not been investigated in detail
in these diseases it is also likely to contribute to cellular
proliferation and survival.
A peptide corresponding to the region of SMRT interacting
with the BCL6-POZ domain has been demonstrated to be
functionally active in vitro and in vivo [26,27]. The peptide prevents
normal germinal center formation in mice and when administered
to BCL6 dependent cell lines or primary lymphoma cells causes
apoptosis. A combination of computer assisted drug design and
screens of small molecule libraries led to the identification of a
compound, 79–6, that binds in the SMRT binding groove in the
BCL6 POZ domain [28]. 79–6 is also functionally active in vivo
and causes apoptosis of BCL6 dependent lymphoma cell lines.
However, there are on-going efforts to carry out further small
molecule library screens for BCL6 inhibitors.
Here we report the identification of a direct interaction between
the BCL6 POZ domain and members of the ansamycin antibiotic
family: rifamycin SV and rifabutin. This represents a novel non-
bactericidal activity of the rifamycin family of antibiotics.
Rifabutin was found to cause the largest chemical shift perturba-
tions by NMR and a crystal structure of BCL6 in complex with
rifabutin reveals new insights into the structure activity relation-
ships required for potential therapeutic agents to disrupt the
SMRT/BCL6 interaction.
Materials and Methods
Luciferase reporter screening assay
A BCL6 reporter construct as previously described [12] was
transfected into DG75 an EBV negative Burkitt’s lymphoma cell
line utilising Nucleofector program O-006 (Lonza Group Ltd,
Basel, Switzerland). A natural product library (TimTec, Newark,
DE, USA) was purchased unsolvated and solvated to a concen-
tration of 10 mM with DMSO. After each compound was
effectively solvated, 5 ml was added to the corresponding wells in
a daughter plate and diluted with 95 ml of sterile water. From the
daughter plate, 3 ml of compound was pipetted into 22 ml of
complete RPMI 1640 in quadruplicate into each different assay
plate. The compounds were diluted into each assay plate at a
concentration of 20 mM. One batch of DG-75 cells was transfected
with BCL6 reporter construct with a standard amount of a
construct expressing Renilla luciferase as a transfection control.
The transfected cells were then incubated at 37uC for 16 to
20 hours. The assay plates were centrifuged and 50 ml of the
transfected cells were pipetted into the designated wells on the
assay plate. The transfected cells were incubated for 12 hours with
the compounds before harvesting and determination of luciferase
activity.
Figure 1. A natural product screen to identify novel inhibitors of BCL6 transcriptional repression. (A) Schematic of BCL6 showing amino-
terminal POZ domain (red), carboxy terminal zinc fingers (yellow) and mid portion containing PEST domains (blue). Different proteins associate with
the three portions of BCL6. NCoR, BCoR and SMRT associate with the POZ domain, MTA3 and NuRD with the mid portion and ETO1 with the zinc
fingers. (B) Illustration of the screening strategy. BCL6 (green) is shown associating with its binding site cloned upstream of a luciferase reporter gene.
Without any compound, or with an inactive compound i.e. one that does not bind BCL6, luciferase output is repressed but in the presence of active
compound BCL6 mediated repression is prevented and output of luciferase increases. (C) Screening results for half a plate (40 compounds) from the
natural product library. The black bar (furthest left) is the mean negative control i.e. transfected cells without test compound, and the black horizontal
line the mean value across the entire screen. The red bar shows rifamycin SV. (D) The effect of rifamycin is due to inhibition of BCL6 transcriptional
repression. HEK293T cells were co-transfected with a BCL6 expression construct and a luciferase reporter. Transcriptional repression due to BCL6 was
relieved by rifamycin SV (R), but not by an agent that was ineffective in the screen (D).
doi:10.1371/journal.pone.0090889.g001
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HEK293T cells were seeded at 26104 cells/well in 96-well
plates and following 24 hours in culture were co-transfected with a
BCL6 reporter vector (100 ng), Renilla luciferase control vector
(100 ng) and a full-length BCL6 expression plasmid (200 ng) using
polyethylenimine (PEI) (Sigma, St. Louis, MO, USA). Compound
(5 mM) was added and cells were lysed, harvested and luciferase
activity determined after 24 hours. Each condition was carried out
in triplicate.
Protein expression and purification
DNA encoding the POZ domain (residues 7 to 128) of human
BCL6 (Figure 1A), with cysteine8 mutated to glutamine,
cysteine67 mutated to arginine and cysteine84 mutated to
asparagine, was cloned into a vector containing a 58-amino
acid GB1 solubility enhancement tag, a 66 histidine affinity tag
and a TEV cleavage site (PROTEX, University of Leicester;
(http://www2.le.ac.uk/department/biochemistry/research-
groups/protex)). Constructs were expressed in the E.coli strain
Rosetta (DE3) (Novagen, Merck Chemicals Ltd., Beeston, UK)
(Figures S1A and S1B). For preparation of 15N-labelled samples
bacteria were cultured 2M9 minimal media containing 1 g of
15N-ammonium chloride per liter. For crystallisation and
fluorescence polarisation E. coli were cultured in 2xYT medium.
Bacteria were cultured at 37uC BCL6-POZ was purified using
Ni-NTA resin and subsequent buffer exchange into 50 mM
sodium phosphate pH 6, 300 mM NaCl, 5 mM DTT. Following
TEV cleavage overnight at 4uC the sample was further purified
by gel filtration using a Superdex S200 column (GE Healthcare,
Amersham, UK). Protein concentrations were measured using
Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA).
Peptide Synthesis and Fluorescence Polarization
Fmoc-protected amino acids were purchased from Novabio-
chem (Merck Chemicals Ltd, Nottingham, UK) or PolyPeptide
Group (Strasbourg, France) (Fmoc-homophenylalanine, Fmoc-
Styrylalanine, Fmoc-1-naphthylalanine & Fmoc-2-naphthylala-
nine) and were used as received. Peptides were synthesized on a
CEM Liberty 1 automated microwave-assisted solid-phase
peptide synthesizer (CEM Corporation, Buckingham, UK) using
a 30 mL Teflon reactor vessel on 0.05 mmol scale using Fmoc-
Arg(Pbf)-Wang resin (100–200 mesh) (substitution: 0.63 mmol/g).
Peptide solutions were made in PBS containing 1 mM tris-(2-
carboxyethylphosphine) and then coupled via the amino-terminal
cysteine to the thiol-reactive BODIPY TMR dye (Invitrogen,
Paisley, UK) in accordance with manufactures instructions.
Unreacted dye was removed by gel filtration using a PD-10
column (GE Healthcare). Fluorescence polarization experiments
were performed in a black 96 well assay plate (Corning,
Amsterdam, The Netherlands). Titrations were performed using
a fixed concentration of SMRT peptide, with increasing
concentration of the BCL6-POZ domain protein, in a final
volume of 100 ml of assay buffer (PBS, 0.05% (v/v) Triton X-
100, 0.1 mg/mL BSA). The plate was mixed by shaking for 1
min and measurements were then taken using a Victor X5 plate
reader (Perkin Elmer, Waltham, MA, USA) at room temperature
with an excitation wavelength of 531 nm and an emission
wavelength of 595 nm. Experiments were performed in triplicate
and data were analysed using GraphPad Prism (version 6.0,
GraphPad Software, Inc., San Diego, CA, USA). Kd values were
calculated by nonlinear curve fitting using a one-site binding
(hyperbola).
NMR spectroscopy
All NMR experiments were performed at 303 K using Bruker
AVANCE DRX 600 or AVANCE AVII 800 spectrometers both
equipped with CryoProbes. Titrations were carried out using
280 mM BCL6-POZ in 50 mM sodium phosphate pH 6,
300 mM NaCl, 5 mM DTT, 5% v/v D2O. Compounds were
resuspended in deuterated DMSO (DMSO-d6). 2D 1H15N
heteronuclear single-quantum correlation (HSQC) spectra were
acquired with transverse relaxation optimization (TROSY) [29]
using 32 scans and 92 increments. 1H15N HSQC spectra were
collected on BCL6-POZ alone and then with increasing amount
of compound. Data were analyzed using CCPN Analysis [30].
Crystallization and X-ray structure determination
Crystals of the BCL6-POZ domain were obtained using the
sitting drop vapor diffusion method at room temperature
(Figure S1) BCL6-POZ was concentrated to 3.8 mg/ml and
crystallised in the presence of rifabutin at a ratio of 1:8. In detail
1 ml of BCL6-POZ in 50 mM sodium phosphate pH 6, 300 mM
NaCl, 5 mM DTT (in the presence or absence of rifabutin) was
mixed with 1 ml reservoir solution (20% PEG 6000, 100 mM
sodium citrate, pH 5). Crystals grew in the space group P1 21 1.
Data were collected to 2.3 A˚ on the microfocus beam line I24 at
the Diamond Light Source, Didcot, Oxfordshire. Data were
processed and integrated using XDS, iMosflm, Pointless and
Aimless [31,32]. The structure was solved using molecular
replacement using Phaser [33] and the BCL6-POZ domain from
the BCL6/SMRT structure (1R2B, [34]). Model fitting and
refinement were performed using Coot and Refmac [35,36].
Statistics of the refinement are presented in Table 1. The Rfree
remained higher than expected probably due to the small size of
the crystals and slightly streaky nature of the diffraction.
Accession numbers
Coordinates and structure factors for the BCL6-POZ domain
(residues 7–128) – Rifabutin complex have been deposited in the
Protein Data Bank (ID code 4CP3).
Results
Natural Product Screen for inhibitors of the BCL6-SMRT
interaction
Natural products form the basis for many drugs in clinical use.
Despite their chemical complexity, they have other properties
such as cell permeability and relatively high bioavailability that
make them attractive starting materials for screens in drug
discovery projects. We screened a commercial natural product
library consisting of 480 compounds for ability to prevent BCL6
induced transcriptional repression in the Burkitt’s lymphoma cell
line DG75 (Figure 1B). Nine compounds modified transcriptional
activity of a reporter construct bearing BCL6 binding sites in
DG75 (3 compounds repressing and 6 compounds enhancing
luciferase activity) (Figure 1C and Figures S2 and S3). However,
the BCL6 DNA binding sequence shares sequence similarities to
that of the STAT family of transcription factors [10] and our
results might reflect inhibition of transcription factors other than
BCL6. Therefore, to show directly that BCL6 transcription was
inhibited we co-transfected a BCL6 expression construct and a
luciferase reporter into HEK293T cells that do not express
endogenous BCL6. Luciferase expression was repressed by BCL6
and this was relieved by the addition of rifamycin SV (labelled R)
(Figure 1D), which was detected in the initial library screen
(Figure 1C), but not by the other eight compounds.
Rifamycin Antibiotics Form a Complex with BCL6
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Rifamycin SV directly interacts with BCL6-POZ
In order to determine whether a direct interaction with BCL6
in solution was responsible for the observed effects on
transcription, we utilized an NMR chemical shift perturbation
assay. Work by others has demonstrated that the important
interactions of BCL6 with co-repressors occur through the
amino-terminal POZ domain, which also mediates homodimer-
isation [37]. The TROSY 1H15N TROSY-HSQC NMR
spectrum of the BCL6-POZ homodimer showed good dispersion
and uniform line widths indicative of a stable well-folded protein
(Figure S4). Addition of rifamycin SV (Figure 2A), resulted in a
subset of peaks shifting in a concentration dependent manner
(Figure 2B) supporting the hypothesis that rifamycin interacts
directly with the BCL6-POZ domain. However, even at large
excesses of rifamycin SV the chemical shift perturbations were
relatively small and chemical shift changes continued to be
detectable at high concentrations demonstrating that binding had
still not reached saturation.
Screening of rifamycin derivatives
Rifamycin SV belongs to a family of ansamycin antibiotics,
which have related structures, comprising a napthoquinone ring
bridged by an aliphatic chain (Figure 2A and 2C). In order to
determine whether other members of the family also bound to the
BCL6-POZ domain we analysed the commercially available
compounds rifabutin, rifapentine, rifampicin and rifaximin as well
as 3-formyl rifamycin, for interaction with the BCL6-POZ
domain.
These derivatives all caused spectral changes of varying
magnitude with the greatest shifts caused by rifabutin (Figure 2C
and 2D). The estimated order of binding from weakest to strongest
was: rifaximin, rifapentine, 3-formyl rifamycin, rifampicin, rifa-
mycin SV and rifabutin. Comparison of the BCL6-POZ domain
spectra on addition of rifamycin SV and rifabutin (Figures 2B and
2D) showed small differences in the observed shifts of some peaks
suggesting minor differences in binding in solution. By plotting the
chemical shift change (dD) of the most shifted peak, as a function of
rifabutin concentration it was possible to estimate the Kd of the
interaction as being in the order of ,1 mM.
Structure of the BCL6-POZ- Rifabutin complex
To explore further the atomic details of the interaction we
crystallized the BCL6-POZ domain in complex with rifabutin.
Complex crystals were readily obtained and easily identified due
to the purple colour of rifabutin (Figure S1C). Molecular
replacement with the BCL6-POZ domain (1R2B, [34]) as search
molecule produced a clear electron density map with extra
density readily identifiable for rifabutin (Figure 3, Table 1).
Despite the BCL6-POZ domain being a symmetrical dimer [2,3]
only one molecule of rifabutin is present per dimer. The rifabutin
is located at the dimer interface and binds to the surface that
overlaps the surface bound by the SMRT and NCoR peptides
[2,34]. The napthoquinone ring of rifabutin occupies the pocket,
which is occupied by the residues histidine1426 of SMRT,
histidine1352 of NCoR, or tryptophan509 of BCOR, in the three
POZ domain co-repressor structures [6]. The most important
interaction appears to be a p-stacking interaction with the
aromatic ring of tyrosine58 of the BCL6-POZ domain. The
aliphatic ‘‘handle’’ or macrocycle of rifabutin makes electrostatic
interactions with asparagine21 and arginine24 (Figure 3).
A small molecule, 79–6, has been described previously and has
been observed to bind in the same pocket at the BCL6:SMRT
interface [28]. Comparison of the binding of SMRT peptide, 79–6
and rifabutin demonstrates remarkable similarities (Figure 4).
Specifically apolar interactions with tyrosine58 and electrostatic
interactions with asparagine21 and arginine24 are involved in the
binding of all three molecules.
SMRT peptide containing artificial amino acids to explore
binding to BCL6-POZ domain
In order to explore the importance of histidine1426 of SMRT
or histidine1352 of NCoR for binding to the pocket in the BCL6-
POZ domain, which is also occupied by rifabutin and 79–6 we
synthesised SMRT/NCoR peptides with artificial amino acids
replacing the histidine (Figure S5). By fluorescence polarisation
the Kd of binding of the BCL6-POZ domain to labelled wild-type
SMRT peptide was determined to be 5 mM. All the artificial
amino acids that were employed in the study showed reduced
binding, as compared to wild-type peptide, but there were
considerable differences in affinity. Whilst the peptide bearing a
1-naphthyl residue had a binding affinity of 11 mM the 2-naphthyl
peptide had a much lower affinity of 154 mM (Figure 5A).
Homophenylalanine and styryl derivatives had intermediate
affinities. Modelling of these artificial amino acids, such that they
have the same orientation as tryptophan509 of BCOR and
histidine1426 of SMRT [6], suggested explanations for this data
(Figure 5B, 5C and 5D). Whilst 1-naphthyl is oriented within the
pocket, 2-naphthyl clashes with the BCL6-POZ domain, which is
likely to prevent significant binding. Homophenylalanine and
Table 1. Data collection and refinement statistics (Molecular
replacement).
BCL6/Rifabutin
Data Collection
Space Group P 1 21 1
Cell dimensions
a,b,c (A˚) 35.17, 54.83, 58.16
a,b,c (˚ ) 90, 95.21, 90
Resolution (A˚) 39.82–2.3 (2.38–2.3)
Rmerge 10.8 (51.8)
I/sI 9.8 (4.1)
Completeness (%) 97.13 (97)
Redundancy 3.0 (2.9)
Refinement
Resolution (A˚) 2.3
No. reflections 9168
Rwork/Rfree 20.2/26.9
No. Atoms 2053
Protein 1969
Ligand/ion 61
Water 23
B-factors
Protein 27.9
Rifabutin 48
Water 24.6
R.M.S. deviations
Bond lengths (A˚) 0.013
Bond angles (˚ ) 1.885
*Highest resolution shell is shown in parenthesis.
doi:10.1371/journal.pone.0090889.t001
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styryl side chains were employed to place aromatic rings,
potentially capable of interacting with tyrosine58 closer to the
BCL6-POZ domain than is histidine1426 in the wild-type
structure. Binding affinity was again reduced demonstrating the
stringent requirements for compounds that are to be lead
molecules as BCL6 inhibitors.
Discussion
There is interest in developing BCL6 inhibitors because this
transcription factor is required for proliferation and survival of
several types of non-Hodgkin’s lymphoma and nodular lympho-
cyte predominant Hodgkin’s lymphoma and proof of principle
studies have demonstrated the efficacy of inhibiting BCL6 in
diffuse large B-cell lymphoma [27,28]. The rifamycins and
especially rifabutin are attractive starting materials for producing
a clinically useful BCL6 inhibitor because of their high lipid
solubility, extensive tissue penetrance and long half-life [38].
We have demonstrated that rifamycin SV and rifabutin,
members of the ansamycin antibiotic family, that have clinical
uses in the prevention or treatment of bacterial infections due to
binding and inhibition of bacterial DNA-dependent RNA
polymerase, are able to bind the BCL6-POZ domain.
This result is functionally significant as demonstrated by
inhibition of BCL6 transcriptional repression by rifamycin SV.
The luciferase reporter assay we employed produced 9 ‘‘hits’’ of
which only rifamycin SV bound to BCL6. Three of the
compounds appeared to enhance transcriptional repression i.e.
reduced luciferase production, and for one of these compounds
(Figure S2A) the explanation may be that it is a known inhibitor of
firefly luciferase (Figure S3B) [39].
Rifamycin SV is derived from rifamycin B (the natural
fermentation product of Streptomyces mediterranei) by removal of
the glycolic group bound to C-4. The rifamycins are potent
inhibitors of bacterial DNA dependent RNA polymerase [40]
and are utilised in the treatment of tuberculosis. Another
property of these compounds, their high lipid solubility, may
help to penetrate the bacterial wall. Structurally, the rifamycins
consist of a naphthoquinonic chromophore, which is spanned by
an aliphatic bridge between the nitrogen on C-2 and the oxygen
on C-12 of the napthoquinone moiety (Figure 2A and 2C). The
members of the family differ primarily in the side chains on C-3
and C-4. We demonstrate that rifamycins bind with different
strengths to the BCL6 POZ domain. These agents largely differ
in the side chain attachments to C-3 and C-4, which do not
appear to make significant interactions with the protein in our
crystal structure. One possibility is that the side-chains alter the
Figure 2. Rifamycin SV and its derivative, rifabutin, bind directly to the BCL6-POZ domain. Schematic diagram to compare the structures
of (A) rifamycin SV and (C) rifabutin. These two compounds differ with respect to the side chains on C-3 and C-4. (B) and (D) TROSY 1H,15N HSQC
spectra of 280 mM BCL6-POZ domain. (B) Chemical shift changes due to rifamycin SV. An overlay of the spectra of BCL6-POZ domain alone (green)
and in the presence of a 16:1 molar ratio of rifamycin (purple). (D) Chemical shift changes due to rifabutin with an overlay of the spectra of BCL6-POZ
domain alone (green) and in the presence of 4:1 (light blue), 8:1 (red) and 16:1 (purple) molar ratios of rifabutin.
doi:10.1371/journal.pone.0090889.g002
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rigidity of the molecule to alter the fit in the lateral groove of the
POZ domain dimer. Supporting the view that the C-3/C-4 side
chains are important in modulating function, others have shown
that rifamycin SV can inhibit amyloid fibril formation through
disruption of interactions between fibril aromatic rings that are
required for elongation whereas rifaximin does not have this
effect [41].
SMRT and NCoR occupy a binding pocket that is present in
the apo i.e. unliganded, form of BCL6. The co-repressor,
BCOR, associates with BCL6 through interactions with the
lateral groove as do SMRT and NCoR. Whilst SMRT and
NCoR bind to the BCL6-POZ domain through identical
sequences, GRSIHEIPR (residues 1422 to 1430 of SMRT and
residues 1348 to 1356 of NCoR), there is no similarity to the
BCL6 binding sequence of BCoR, APSSWVVPG. However,
binding of peptides derived from SMRT and BCoR have been
investigated in detail [6]. BCOR tryptophan509 and SMRT
histidine1426 make similar contacts on the BCL6-POZ domain,
namely with residues methionine51, cysteine53, serine54, gly-
cine55, asparagine21, arginine24 and arginine28 [6]. The small
molecule, 79–6, utilizes a subset of the interactions employed by
the SMRT peptide for binding to the BCL6 POZ domain. Our
X-ray crystallographic studies show that rifabutin occupies the
pocket utilised by histidine in the SMRT and NCoR sequences
and tryptophan in BCoR. The binding of rifabutin to the BCL6
POZ domain also appears very similar to that of the small
molecule, 79–6, [28]. Collectively it seems likely that rifamycin
SV and rifabutin can occupy a druggable pocket in the BCL6-
POZ domain.
Macrocyclic compounds, of which rifamycin SV and rifabutin
are examples, may have utility in perturbing protein-protein
interactions and are also highly membrane permeable. We suggest
that the rifamycins will be interesting compounds from which to
develop BCL6 inhibitors.
Supporting Information
Figure S1 Protein purification and crystallisation of
BCL6. (A) Coomassie stained polyacrylamide gel showing
production of BCL6-POZ domain with a GB1 tag and TEV
cleavage of the tag. (B) BCL6-POZ domain purified away from the
GB1 tag by size exclusion gel filtration. Coomassie stained
Figure 3. Crystal structure of rifabutin and BCL6-POZ domain.
Electron density corresponding to rifabutin, following refinement, in the
context of surrounding electron density demonstrating the proximity of
(A) tyrosine58 from one monomer of the POZ dimer and (B)
asparagine21 and arginine24 from the other monomer. (C) Surface
representation of BCL6-POZ with basic residues (including asparagine21
and arginine24) in blue and acidic residues in red. The napthoquinone
rings of rifabutin are in proximity to tyrosine58 whilst the aliphatic
bridge is adjacent to the basic surface.
doi:10.1371/journal.pone.0090889.g003
Figure 4. BCL6-POZ domain in complex with rifabutin, 79–6
and the SMRT peptide. A section of the BCL6-POZ domain structure
is shown binding; (A) rifabutin, (B) the SMRT peptide and (C) 79–6.
doi:10.1371/journal.pone.0090889.g004
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polyacrylamide gel showing fractions collected. (C) BCL6-POZ
crystal mounted in a loop at the Diamond Synchrotron beamline
I24 (Red box 25.9 mm2). The crystals are faintly lilac having taken
up the coloured rifabutin.
(TIF)
Figure S2 Natural product library screening. Results for
all 480 compounds are presented. Column to the left in orange is
the mean negative control i.e. transfected cells without test
compound, and the orange horizontal line the mean value across
the entire screen. Compounds considered ‘‘its’’are represented as
red columns and comprise 6 that relieve BCL6 transcriptional
repression and 3, which appear to enhance repression.
(TIF)
Figure S3 Structures of the 9 compounds that alter
BCL6 transcriptional repression. The most widely used
compound name is presented apart from one compound (A),
which has no common name and for which the IUPAC
nomenclature is stated. The chemical identifier (CID) from
PubChem is also presented. (A to C) Three compounds that
reduce luciferase activity. (D to I) Compounds that enhance
luciferase activity, including (I) Rifamycin SV.
(TIF)
Figure S4 TROSY 1H, 15N HSQC NMR spectrum of the
BCL6-POZ domain.
(TIF)
Figure S5 Sequences of SMRT peptides. Sequences of
SMRT peptides utilised in fluorescence polarisation experiments
together with the structures of the artificial amino acids at the
position of histidine1426 in the wild-type peptide. (A) wild-type
SMRT, (B) 1-naphthyl-SMRT, (C) 2-naphthyl-SMRT, (D)
homophenylalanine-SMRT and (E) styryl-SMRT.
(TIF)
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